232 related articles for article (PubMed ID: 20601285)
1. Osteoblast function in myeloma.
Roodman GD
Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
3. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
4. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
5. Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor.
Karadag A; Scutt AM; Croucher PI
J Bone Miner Res; 2000 Oct; 15(10):1935-43. PubMed ID: 11028445
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
7. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
8. TGF-β-related mechanisms of bone destruction in multiple myeloma.
Matsumoto T; Abe M
Bone; 2011 Jan; 48(1):129-34. PubMed ID: 20570621
[TBL] [Abstract][Full Text] [Related]
9. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
11. Rat hindlimb unloading by tail suspension reduces osteoblast differentiation, induces IL-6 secretion, and increases bone resorption in ex vivo cultures.
Grano M; Mori G; Minielli V; Barou O; Colucci S; Giannelli G; Alexandre C; Zallone AZ; Vico L
Calcif Tissue Int; 2002 Mar; 70(3):176-85. PubMed ID: 11907715
[TBL] [Abstract][Full Text] [Related]
12. The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
Kassen D; Moore S; Percy L; Herledan G; Bounds D; Rodriguez-Justo M; Croucher P; Yong K
Br J Haematol; 2014 Oct; 167(2):194-206. PubMed ID: 25079197
[TBL] [Abstract][Full Text] [Related]
13. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
15. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2.
Rickard DJ; Sullivan TA; Shenker BJ; Leboy PS; Kazhdan I
Dev Biol; 1994 Jan; 161(1):218-28. PubMed ID: 8293874
[TBL] [Abstract][Full Text] [Related]
16. Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts.
Heino TJ; Hentunen TA; Väänänen HK
Exp Cell Res; 2004 Apr; 294(2):458-68. PubMed ID: 15023534
[TBL] [Abstract][Full Text] [Related]
17. Effects of methotrexate on human osteoblasts in vitro: modulation by 1,25-dihydroxyvitamin D3.
Scheven BA; van der Veen MJ; Damen CA; Lafeber FP; Van Rijn HJ; Bijlsma JW; Duursma SA
J Bone Miner Res; 1995 Jun; 10(6):874-80. PubMed ID: 7572311
[TBL] [Abstract][Full Text] [Related]
18. 17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.
Li Q; Yu K; Tian X; Kong F; You Y; Chen Z; Zou P
Leuk Res; 2009 Sep; 33(9):1266-71. PubMed ID: 19167063
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
[TBL] [Abstract][Full Text] [Related]
20. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]